Investors are waking up to Centessa's sleepiness drug | BioPharma Dive
Centessa Pharmaceuticals plans to rapidly advance its experimental drug after a small study showed significant increase in time to sleep in healthy volunteers. The company intends to start mid-stage studies by year-end, evaluating the drug against narcolepsy and idiopathic hypersomnia. Centessa's CEO, Saurabh Saha, noted the data exceeded expectations, leading to accelerated development. The drug targets orexin proteins, with potential for a 1 mg, once-daily treatment, comparing favorably to Takeda's candidate. The study used Maintenance of Wakefulness Tests, showing the drug restored normative wakefulness with favorable safety and tolerability.
Related Clinical Trials
Reference News
Centessa Pharmaceuticals plans to rapidly advance its experimental drug after a small study showed significant increase in time to sleep in healthy volunteers. The company intends to start mid-stage studies by year-end, evaluating the drug against narcolepsy and idiopathic hypersomnia. Centessa's CEO, Saurabh Saha, noted the data exceeded expectations, leading to accelerated development. The drug targets orexin proteins, with potential for a 1 mg, once-daily treatment, comparing favorably to Takeda's candidate. The study used Maintenance of Wakefulness Tests, showing the drug restored normative wakefulness with favorable safety and tolerability.
Centessa Pharmaceuticals' Phase 1 trial of ORX750, an orexin receptor 2 agonist, showed significant improvement in wakefulness with no severe adverse events, positioning the drug for Phase 2 trials in narcolepsy and idiopathic hypersomnia.
Centessa's ORX750, an OX2R agonist, showed significant wakefulness improvements in a phase 1 trial, with the 2.5 mg dose restoring normal wakefulness. ORX750 was safe and well-tolerated, prompting plans for phase 2 trials in narcolepsy types 1 and 2, and idiopathic hypersomnia starting late 2024.